Discover
NTHI
NeOnc Technologies Holdings, Inc.
4.46
1 x 4.67
1 x 4.49
bid
ask
-
0.07
1.55%
1 @ 04:00 PM
4.37 -0.09 (2.09%)
| Ytd | -46.07% | |
| 1y | 33.13% |
4.28
day range
4.53
3.20
52 week range
12.99
| Open | 4.45 | Prev Close | 4.53 | Low | 4.28 | High | 4.53 | Mkt Cap | 115.66M |
| Vol | 80.08K | Avg Vol | 93.65K | EPS | -1.80 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 4.87 | 200-d Avg | 7.99 | 1yr Est | 0.00 |
NTHI News
globenewswire.com
Wall Street is Watching These Biotechs
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDA
benzinga.com
NeOnc Technologies Granted Investigational New Drug Status From Abu Dhabi's Department Of Health For
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clini
benzinga.com
NeOnc Technologies Proceeding Ahead With Pipeline Of Therapies After Receiving Department of Health
NeOnc Technologies Holdings (NASDAQ:NTHI) is rapidly emerging as a development-stage neuro-oncology
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
NeOnc Announces Abu Dhabi DOH Grants IND Status For NEO212, Orally Administered Perillyl Alcohol-Tem
Clearance enables Phase 2 evaluation of NEO212, the Company's oral perillyl alcohol-temozolomide
benzinga.com
NeOnc Technologies Enters Securities Purchase Agreement For Up To $5,000,000 Of Its Convertible Pref
The transactions contemplated by the Purchase Agreement are expected to close upon the satisfaction